Streetbeat News

Revenues

LTHM

Livent Corporation has reduced its 2023 revenue guidance from $1.025B-$1.125B to $890M-$940M, which is below the estimated $1.06B.

Portfolio Pulse from Benzinga Newsdesk

October 31, 2023 | 8:30 pm

DEI

Douglas Emmett Inc has reported its Q3 revenue at $255.4M and FFO per share at $0.45.

Portfolio Pulse from Benzinga Newsdesk

October 31, 2023 | 8:23 pm

AMD

AMD's Q3 data center revenue was reported at $1.6B, showing no year-on-year change. The client segment revenue increased by 42% YoY to $1.5B, while the embedded segment revenue decreased by 5% YoY to $1.2B.

Portfolio Pulse from Benzinga Newsdesk

October 31, 2023 | 8:20 pm

TCS

The Container Store Group has revised its FY23 EPS from $0.05-$0.15 to $(0.24)-$(0.13) and its revenue from $875M-$890M to $870M-$885M. The company also provided its financial outlook for the fiscal third quarter ending on December 30, 2023, and the full year ending March 30, 2024. The company plans to open four new small format stores in the remainder of fiscal 2023 and four new stores in fiscal 2024.

Portfolio Pulse from Benzinga Newsdesk

October 31, 2023 | 8:14 pm

LBTYA

LBTYB

LBTYK

Liberty Global has reported its Q3 consolidated revenue on a rebased basis to be $1.8545 billion.

Portfolio Pulse from Benzinga Newsdesk

October 31, 2023 | 8:07 pm

GOOG

META

21-year-old college student Jayson Siu turned a sticker side hustle into a $500,000 business using social media. His business, Invalid.jp, generated $512,000 in revenue last year. He expanded marketing efforts to Alphabet Inc's Google, and Meta Platform Inc's Facebook and Instagram. He continues to add new product lines and resell them online.

Portfolio Pulse from Adam Eckert

October 31, 2023 | 7:50 pm

BLD

TopBuild's shares are trading higher following the company's announcement of better-than-expected Q3 financial results and an increased FY23 revenue outlook.

Portfolio Pulse from Benzinga Newsdesk

October 31, 2023 | 7:04 pm

CTLT

SRPT

Catalent Inc's (CTLT) shares are trading lower due to its significant exposure to Sarepta Therapeutics Inc (SRPT) following disappointing data from a pivotal gene therapy trial. Sarepta accounted for nearly 10% of total revenue and roughly 30% of non-COVID biologics revenue in fiscal 2023 for Catalent. The company anticipates 30% Y/Y growth in non-COVID biologics revenue for FY24, primarily fueled by a 60%-plus expansion attributed to Sarepta. However, if Sarepta's Elevidys' label expansion falls short of expectations, it could significantly impact Catalent's future.

Portfolio Pulse from Vandana Singh

October 31, 2023 | 7:03 pm

CHWY

Morgan Stanley analyst Lauren Schenk has upgraded Chewy Inc (NYSE:CHWY) to Overweight from Equal-Weight, despite lowering the price target from $31 to $28. Schenk notes that CHWY's decline of over 50% since mid-July due to customer growth concerns is overdone. She sees CHWY still gaining market share and expects better-than-expected revenue growth and ongoing margin expansion. She also forecasts CHWY’s EBITDA margin of 5% and 10% in FY25 and FY30, respectively.

Portfolio Pulse from Lekha Gupta

October 31, 2023 | 6:25 pm

STLA

Stellantis reported a 7% year-over-year increase in Q3 revenue, leading to a rise in its share prices.

Portfolio Pulse from Benzinga Newsdesk

October 31, 2023 | 3:46 pm